Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Kringle Pharma, Inc.
  6. News
  7. Summary
    4884   JP3270790003

KRINGLE PHARMA, INC.

(4884)
  Report
Delayed Japan Exchange  -  11:10:12 2023-01-29 pm EST
662.00 JPY   -4.89%
01/18Bank of Japan's Dovish Policy Bolsters Japanese Shares; Shionogi Proceeds with Pediatric Trial of COVID-19 Vaccine
MT
01/18Kringle Pharma Enrolls Initial Candidate in Clinical Study for Vocal Impairment Treatment
MT
01/16Kringle Pharma, Inc. Announces First Patient Enrollment in Phase III Clinical Study for the Treatment of Vocal Fold Scar
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Kringle Pharma : Update on the Investigator-initiated Phase 2 Study in Patients with ALS

08/12/2022 | 03:10am EST

Press release

12 August, 2022

Update on the Investigator-initiated Phase 2 Study in Patients with ALS

Kringle Pharma, Inc. (Head office located in Osaka, Japan; President & CEO, Kiichi Adachi; "KRINGLE"), a late clinical-stage biopharmaceutical company, today announces that it has received the results of the investigator-initiated phase 2 clinical study evaluating its recombinant human HGF (KP-100IT) for the treatment of amyotrophic lateral sclerosis (ALS) from Tohoku University, located in Miyagi, Japan.

The study was a randomized, double-blind,placebo-controlled, phase 2 clinical study to evaluate the efficacy and safety of KP-100IT in a total of 46 ALS patients with Japan ALS Severity Classification of Grade 1 or 2, within 30 months of onset of the disease. KP-100IT (for 32 patients) or placebo (for 14 patients) was administered intrathecally once every two weeks, and the change in ALSFRS-R score at the 24-week treatment period was evaluated as a primary endpoint. As a result, there was no statistically significant difference between the KP-100IT group and the placebo group. No statistically significant differences were observed in the pre-specified secondary endpoints between the two groups. On the other hand, in the KP- 100IT administered group, slowing of the disease progression was observed in some cases and further detailed analysis is required to interpret the results of this study. Regarding safety, the incidence of adverse events was similar between the KP-100IT and placebo groups, confirming that the intrathecal administration of KP-100IT was well-tolerated. KRINGLE will discuss with Tohoku University to determine the potential next step of development based on the results of further detailed analysis of the study.

About Amyotrophic Lateral Sclerosis (ALS)

ALS is an intractable neurodegenerative disease that gradually impairs motor function due to degeneration of motor neurons. In Japan, it is reported that approximately 10,000 patients are designated to have ALS. The causes of ALS are various, reportedly including genetic association or glutamate toxicity, but mostly unknown. The common symptom is muscle atrophy caused by motor neuron damage and loss, and therefore protection of motor neurons is considered beneficial for the therapeutic efficacy.

About Japan ALS Severity Classification

Severity of ALS is classified from Grade 1 (least severe) to Grade 5 (most severe) defined by Japan Ministry of Health, Labor and Welfare Specific Disease Research Group.

About ALS Functional Rating Scale-Revised(ALSFRS-R)

The ALSFRS-R measures 12 aspects of physical functions from one's daily life. Each function is scored from 4 (normal) to 0 (no ability), with a total score of maximum 48 to minimum 0.

For more information, please contact

Daichika Hayata

Director, Pharmaceutical Development

Kringle Pharma, Inc.

  • +81-72-641-8739 kpinfo@kringle-pharma.com

Disclaimer

Kringle Pharma Inc. published this content on 12 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 August 2022 07:09:13 UTC.


ę Publicnow 2022
All news about KRINGLE PHARMA, INC.
01/18Bank of Japan's Dovish Policy Bolsters Japanese Shares; Shionogi Proceeds with Pediatri..
MT
01/18Kringle Pharma Enrolls Initial Candidate in Clinical Study for Vocal Impairment Treatme..
MT
01/16Kringle Pharma, Inc. Announces First Patient Enrollment in Phase III Clinical Study for..
CI
01/12Kringle Pharma, Inc. Provides Update on Progress of Phase 3 Clinical Trial in Patients ..
CI
2022Kringle Pharma, Inc. Provides Consolidated Earnings Guidance for Year Ending September ..
CI
2022Japan Shares Turn Red on Tokyo Inflation, Protests Over China Lockdown; Shionogi Seeks ..
MT
2022Kringle Pharma Starts Clinical Trial for Treatment of Vocal Impairment; Shares Up 7%
MT
2022Kringle Pharma, Inc. Announces Initiation of Phase III Study of HGF in Vocal Fold Scar
CI
2022Kringle Pharma Seeks Clinical Trial Approval for Treatment of Vocal Impairment
MT
2022Kringle Pharma, Inc. Submits Clinical Trial Application
CI
More news
Financials
Sales 2022 391 M 3,01 M 3,01 M
Net income 2022 -331 M -2,55 M -2,55 M
Net cash 2022 2 756 M 21,2 M 21,2 M
P/E ratio 2022 -6,60x
Yield 2022 -
Capitalization 3 745 M 28,8 M 28,8 M
EV / Sales 2021 6,17x
EV / Sales 2022 -0,86x
Nbr of Employees 12
Free-Float 73,1%
Chart KRINGLE PHARMA, INC.
Duration : Period :
Kringle Pharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KRINGLE PHARMA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Managers and Directors
Kiichi Adachi Manager-Research & Development
Yutaka Matsuura Manager-Business Administration
Kohichiro Yoshino Independent Outside Director
Akihiro Tomoyasu Director
Etsuro Hashimura Director & Manager-Reliability Assurance
Sector and Competitors
1st jan.Capi. (M$)
KRINGLE PHARMA, INC.21.68%29
MODERNA, INC.5.42%72 745
LONZA GROUP AG17.24%42 787
IQVIA HOLDINGS INC.12.00%42 622
ALNYLAM PHARMACEUTICALS, INC.-2.64%28 465
SEAGEN INC.9.46%26 117